Pyridoxamine, an inhibitor of advanced glycation end products (AGEs), appears to protect against pathological changes in the retinas of diabetic rats and may be a new treatment for diabetic retinopathy, researchers report.
“This preclinical study is a demonstration of efficacy of pyridoxamine in preventing aspects of diabetic retinopathy in an experimental animal model,” Dr. Alan Stitt from Royal Victoria Hospital, Belfast, Northern Ireland, told Reuters Health.
תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!